Mental Health World Conference 2026
Scientific Sessions
Psychedelic Assisted Therapies Clinical Trials and Ethical Frontiers
At the Mental Health World Conference (MHWC 2026), this cutting edge session explores clinical and ethical considerations in psychedelic assisted psychotherapy, including agents such as psilocybin, MDMA, and ketamine. Experts in psychiatry, pharmacology, and ethics will present emerging research findings and discuss regulatory, safety, and access challenges.
The discussion will elaborate on the neurological processes behind psychedelic assisted therapy approaches and their impacts on neural plasticity, emotional processing, and treatment for resistant mental disorders like major depressive disorder, PTSD, and anxiety disorders. Advancements from clinical studies and field research will be covered to understand their effectiveness, duration, and suitability for different patients.
Furthermore, issues such as informed consent, psychological well being, equal access, and the prevention of misuse and exploitation will be explored. The necessity of a therapeutic setting, professional facilitation, and integration therapy will also be addressed by experts to establish appropriate safety measures for the therapy process.
One of the central topics that will be explored is regulatory pathways, policies from around the world regarding the implementation of these therapy techniques, and how they could be integrated into existing medical practices. With the help of cases and scientific discoveries presented during the session, the attendees will learn more about how psychedelic-assisted treatments can change the face of psychiatry.
Related Sessions
Welcome to the Mental Health World Conference (MHWC 2026)
Join us in advancing the frontiers of mental wellness at this globally renowned event de ...
Read More>>
Organizer
